Newsroom
Urovalve Selected to Participate in NIH-Commercialization Assistance Program
SEPTEMBER 11, 2007
Newark, N.J., September 11, 2007 - Urovalve, Inc., has been selected to participate in the 2007-2008 NIH SBIR Commercialization Assistance Program (CAP). The CAP, now in its fourth year of implementation, has been designed and structured to help SBIR Phase II awardees meet the challenges of bringing their technologies to market.
"We are very pleased to have been selected for this competitive program." says Harvey D. Homan, President & CEO of Urovalve, Inc." The program is customized to meet the needs of early stage or advanced companies and is comprised of training and informational workshops, individual mentoring and consulting sessions, and public events in which companies will present their technologies to the biomedical, biotechnology, and healthcare investment, industry and professional service communities. “We are confident that this program will help improve our skills and expand our network to help us achieve success.”
About Urovalve, Inc.
Urovalve, Inc. (www.urovalve.com) is a privately held company located in the Enterprise Development Center at New Jersey Institute of Technology in Newark, New Jersey. The company develops superior medical devices to address problems with urinary flow and control.